IOL Chemicals and Pharmaceuticals Ltd reported a strong performance for the September 2025 quarter, posting a significant rise in profitability and operational efficiency. The company’s shares surged up to 13% during the session, reversing a recent downward trend.
Financial Highlights (Q2 FY25, YoY)
- Net Profit: ₹30 crore, up 56.3% from ₹19.2 crore
- Revenue from Operations: ₹567.5 crore, up 8% from ₹525.8 crore
- EBITDA: ₹57 crore, up 37% year-on-year
- Operating Margin: 10%, compared to 7.9% in the year-ago quarter
The margin improvement was attributed to enhanced production efficiency and a balanced product mix, which supported higher profitability.
Business Overview
IOL Chemicals operates in both the pharmaceutical and specialty chemicals segments, manufacturing active pharmaceutical ingredients (APIs) and value-added chemicals for domestic and global markets. The company is among the world’s leading producers of Ibuprofen, with an estimated 35% global market share.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.